Advanced search
Publication Cover
Postgraduate Medicine Volume 132, 2020 - Issue 8
Submit an article Journal homepage
1,257
Views
0
CrossRef citations to date
0
Altmetric
Clinical focus: Cardiometabolic conditions- Editorial

Oral glucagon-like peptide-receptor agonists (GLP1RA) counseling: comparison with insulin counseling

Sanjay Kalraa Department of Endocrinology, Bharti Hospital Karnal, Karnal, IndiaCorrespondence[email protected]
,
Atul Kalhanb Endocrinology, Royal Glamorgan Hospital, Cardiff, United Kingdom of Great Britain and Northern Ireland
&
Lori Berardc Diabetes Management and Clinical Trial Operations - Nurse Consultant, Winnipeg, Manitoba, Canada
Pages 663-666 | Received 22 Jul 2020, Accepted 11 Aug 2020, Published online: 19 Oct 2020

References

  • Cavaiola TS, Pettus JH. Management of type 2 diabetes: selecting amongst available pharmacological agents. In: Feingold KR, Anawalt B, Boyce A, et al. editors Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc; 2017 [cited Mar 31]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425702/
  • Powell PW, Corathers SD, Raymond J, et al. New approaches to providing individualized diabetes care in the 21st century. Curr Diabetes Rev. 2015;11(4):222–230.
  • Peyrot M, Burns KK, Davies M, et al. Diabetes Attitudes Wishes and Needs 2 (DAWN2): a multinational, multi-stakeholder study of psychosocial issues in diabetes and person-centred diabetes care. Diabetes Res Clin Pract. 2013;99(2):174–184.
  • Frid AH, Hirsch LJ, Menchior AR, et al. Worldwide injection technique questionnaire study: population parameters and injection practices. Mayo Clin Proc. 2016;91(9):1212–1223.
  • Kalra S, Kalra B. Counselling patients for GLP-1 analogue therapy: comparing GLP-1 analogue with insulin counselling. N Am J Med Sci. 2012;4(12):638–640.
  • Thethi TK, Pratley R, Meier JJ. Efficacy, safety and cardiovascular outcomes of once-daily oral semaglutide in patients with type 2 diabetes: the PIONEER programme. Diabetes Obes Metab. 2020;22(8):1263–1277.
  • Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial [published correction appears in Lancet. 2019 Jul 6;394(10192):e1]. Lancet. 2019;394(10192):39–50.
  • Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial. JAMA. 2019;321(15):1466–1480.
  • Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care. 2019;42(12):2272–2281.
  • Bain SC, Hansen BB, Malkin SJP, et al. Oral semaglutide versus empagliflozin, sitagliptin and liraglutide in the UK: long-term cost-effectiveness analyses based on the PIONEER clinical trial programme. Diabetes Ther. 2020;11(1):259–277.
  • Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–851. .
  • Vilsbøll T, Bain SC, Leiter LA, et al. Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889–897.
  • Kalra S, Gupta Y. Social pharmacology and diabetes. Indian J Pharmacol. 2014 Oct 1;46(5):564.
  • Kalra S, Das AK, Sahay RK, et al. Consensus recommendations on GLP-1 RA use in the management of type 2 diabetes mellitus: South Asian task force. Diabetes Ther. 2019;10(5):1645–1717.
  • Kalra S, Ganapathi M, Mithal A. Glycemic monitoring with once-weekly glucagon-like peptide 1 receptor agonist (GLP1RA) use. Indian J Endocrinol Metab. 2015 Mar;19(2):193.
  • Lean ME, Carraro R, Finer N, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(5):689–697.
  • Koch KL, Calles-Escandón J. Diabetic gastroparesis. Gastroenterol Clin North Am. 2015;44(1):39–57.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.